Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 2Recruiting 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Prostatic Neoplasms 3Breast Neoplasms 2Toxemia 1Primary Ovarian Insufficiency 1Polycystic Ovary Syndrome 1Pancreatic Neoplasms 1Neuroendocrine Tumors 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Glioblastoma 1Diabetes, Gestational 1Cardiovascular Diseases 1Brain Neoplasms 1

Interventions

Rituximab 21Cyclophosphamide 21fludarabine 12fludarabine phosphate 10pirtobrutinib 6obinutuzumab 6ibrutinib 6acalabrutinib 6Tacrolimus 6Mycophenolic Acid 6Melphalan 6Magnetic Resonance Spectroscopy 6Biopsy 6venetoclax 5tocilizumab 5X-Rays 5Whole-Body Irradiation 5Specimen Handling 5Prednisone 5Phantoms, Imaging 5Peripheral Blood Stem Cell Transplantation 5Nuclear Medicine Department, Hospital 5Etoposide 5Doxorubicin 5Thiotepa 4Lenalidomide 4Granulocyte Colony-Stimulating Factor 4Filgrastim 4Cytarabine 4Bendamustine Hydrochloride 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Lymphoma, Non-Hodgkin × Positron-Emission Tomography × Clear all
NCT03789240 2026-03-03

Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
33 enrolled 17 charts
Lymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡